Topical corticosteroids in plaque psoriasis: A systematic review of efficacy and treatment modalities

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue SUPPL. 3, 2012, Pages 36-46

  Castela, E ^a   Archier, E ^b   Devaux, S ^c   Gallini, A ^d   Aractingi, S ^e   Cribier, B ^f   Jullien, D ^g   Aubin, F ^h   Bachelez, H ⁱ   Joly, P ^j   Le Maitre M ^k   Misery, L ^l   Richard, M A ^b   Paul, C ^c   Ortonne, J P ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d Faculté de Médecine Centre Hospitalo universitaire   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j UNIVERSITÉ DE ROUEN   (France)

^k NONE

^l BREST UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO;

DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; BANDAGES; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860180552     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04522.x     Document Type: Review

References (87)

1. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138. (Pubitemid 46835379)
2. Murphy G, Reich K,. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol 2011; 25: 3-8.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
4. Paul C, Gallini A, Archier E., et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. JEADV 2012; 26 (Suppl. 3): 1-10.
5. Shupack JL, Jondreau L, Kenny C, et al. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 1993; 186: 129-132. (Pubitemid 23070156)
6. Sears H.W,. A double-blind, randomized, placebo-controlled evaluation of the efficacy and safety of hydrocortisone buteprate 0.1% cream in the treatment of psoriasis. Adv Ther 1997; 14: 140-149. (Pubitemid 27314037)
7. Peharda V, Gruber F, Prpic L, Kastelan M, Brajac I,. Comparison of mometasone furoate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris. Acta Dermatovenerol Croat. 2000; 8: 223-226. (Pubitemid 32052943)
8. Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41: 269-274. (Pubitemid 34773449)
9. Katz HAA,. A comparison of the efficacy and safety of the combination mometasone furoate 0,1%/ salicylic acid 5% ointment with each of its components in psoriasis. J Dermatol Treat 1998; 3: 151-156.
10. Huntley AC, Isseroff R,. Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis. Cutis 1985; 35: 489-492. (Pubitemid 15004701)
11. Fabry H, Yawalkar SJ,. A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res 1983; 11: 26-30. (Pubitemid 13178071)
12. Ellis CN, Katz HI, Rex IHJ, et al. A controlled clinical trial of a new formulation of betamethasone dipropionate cream in once-daily treatment of psoriasis. Clin Ther 1989; 11: 768-774. (Pubitemid 20028306)
13. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31: 755-759. (Pubitemid 24340746)
14. Roberts DT,. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis 1996; 57: 27-31.
15. Olsen EA,. Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. Cutis 1996; 57: 57-61.
16. Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol 1997; 136: 89-93. (Pubitemid 27016181)
17. Mensing H, Korsukewitz G, Yawalkar S,. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol 1991; 25: 1149-1152.
18. Lowe N, Feldman SR, Sherer D, et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 2005; 16: 158-164. (Pubitemid 41364775)
19. Leibsohn E,. Comparison of diflorasone diacetate and betamethasone dipropionate ointment in the treatment of psoriasis. J Int Med Res 1982; 10: 22-27. (Pubitemid 12212346)
20. Lebwohl MG, Medansky RS, Savin RC, Alton AV,. Diflorasone diacetate cream in an optimized vehicle versus fluocinonide cream for the treatment of psoriasis. J Dermatol Treat 1995; 6: 219-222. (Pubitemid 26033534)
21. Krueger GG, O'Reilly MA, Weidner M, et al. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. J Am Acad Dermatol 1998; 38: 186-190. (Pubitemid 28100831)
22. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20: 283-291. (Pubitemid 28241748)
23. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris-clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16: 804-811. (Pubitemid 17055883)
24. Jegasothy B, Jacobson C, Levine N, et al. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol 1985; 24: 461-465. (Pubitemid 15246727)
25. Jacobson C, Cornell RC, Savin RC,. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. Cutis 1986; 216: 218-220.
26. Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25: 1145-1148.
27. Fredriksson T, Salde L,. A double-blind trial of budesonide and betamethasone- 17,21-dipropionate in psoriasis. Curr Med Res Opin 1982; 8: 171-177. (Pubitemid 12031648)
28. Decroix J, Pres H, Tsankov N, et al. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 2004; 74: 201-206. (Pubitemid 39330125)
29. Choonhakarn C, Busaracome P, Sripanidkulchai B, et al. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol 2010; 24: 168-172.
30. Blum G, Yawalkar S,. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25: 1153-1156.
31. Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol 1991; 25: 1170-1174.
32. Aggerwal A, Maddin S,. Alclometasone dipropionate in psoriasis: a clinical study. J Int Med Res 1982; 10: 414-418. (Pubitemid 13247446)
33. Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303-307. (Pubitemid 32843785)
34. Singh S, Reddy DC, Pandey SS,. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000; 43: 61-65. (Pubitemid 30439714)
35. Pierard GE, Lachapelle JM, Frentz G, Schopf E, Stolz E,. Hydrocortisone 17-butyrate topical emulsion (Locoid Crelo(registered trademark)) in psoriasis. J Eur Acad Dermatol Venereol 1996: 11-14. (Pubitemid 26038822)
36. Mraz S, Leonardi C, Colõn LE, et al. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J Dermatolog Treat 2008; 19: 354-359.
37. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393. (Pubitemid 35356768)
38. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006; 78: 348-354. (Pubitemid 44952097)
39. Gottlieb AB, Ford RO, Spellman MC,. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185-192. (Pubitemid 36859094)
40. Gip L, Søndergaard J, Thestrup-Pedersen K,. A double blind comparison of betamethoasone 17-valerate 0.1% Lipocream and betamethasone 17-valerate 0.1% ointment in the treatment of patients with psoriasis vulgaris. Eur J Clin Res 1994; 5: 27-31.
41. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-471.
42. Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol 1991; 25: 1175-1178.
43. Senter TP, Stimson DH, Charles G, et al. Comparison of two therapeutic regimens using the same topical corticoid for stable psoriasis. West J Med 1983; 139: 657-662. (Pubitemid 14207243)
44. Larry E, Millikan LE, Mroczkowski TF,. A comparative study of amcinonide and halcinonide 0.1% ointments in the treatment of psoriasis. Int J Dermatol 1986; 25: 542. (Pubitemid 17174315)
45. Sefton J, Loder JS, Kyriakopoulos AA,. Clinical evaluation of hydrocortisone valerate 0.2% ointment. Clin Ther 1984; 6: 282-293. (Pubitemid 14129398)
46. Cornell RC,. Comparison of amcinonide ointment 0.1 percent twice daily and fluocinonide ointment 0.05 percent three times daily in the treatment of psoriasis. Cutis 1983; 31: 566-569. (Pubitemid 13088344)
47. Frost P, Horwitz SN,. Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis. J Int Med Res 1982; 10: 375-378. (Pubitemid 12029158)
48. De Villez RL,. Efficacy and safety of mometasone furoate 0.1% once daily versus fluticasone propionate 0.005% twice daily in the management of psoriasis. Adv Ther 1998; 15: 92-97. (Pubitemid 28247137)
49. Greenspan A, Herndon JH Jr, Baker MD, Cheney T,. Controlled evaluation of 0.05% desonide lotion and desonide cream in psoriasis. Curr Therapeu Res-Clin Exp 1993; 53: 614-620. (Pubitemid 23261635)
50. Chuang T-Y S,. Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone diacetate ointment for psoriasis-a multicentre, randomized, double-blinded study. J Dermatol Treat 1991; 2: 63-66.
51. Koo J, Blum RR, Lebwohl M,. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 2006; 55: 637-641. (Pubitemid 44436646)
52. Katz HI, Prawer SE, Watson MJ,. Comparison of therapeutic efficacy of two different preparations of fluocinonide cream in the treatment of Psoriasis vulgaris. Drug Invest 1991; 3: 3.
53. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: 443-447.
54. Ellis CN, Horwitz SN, Menter A,. Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Curr Therapeu Res-Clin Exp 1988; 44: 315-324. (Pubitemid 19002095)
55. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-632. (Pubitemid 29404798)
56. Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17: 390-401.
57. Leer JAJ,. Efficacy of a betamethasone dipropionate topical glycol preparation in the management of severe psoriasis. Clin Ther 1980; 3: 156-167.
58. Van de Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-176.
59. Willis I, Cornell RC, Penneys NS, et al. Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clin Ther 1986; 8: 275-282. (Pubitemid 16090351)
60. VanderPloeg DE, Cornell RC, Binder R, et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% apllied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica 1989; 15: 145-152. (Pubitemid 19192615)
61. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: 31-36. (Pubitemid 40283322)
62. Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004; 15: 360-364. (Pubitemid 39657846)
63. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: 678-683. (Pubitemid 24344055)
64. Jemec GBE, Ganslandt C, Ortonne J, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-463.
65. Jemec GBE, van de Kerkhof PCM, Enevold A, et al. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. J Eur Acad Dermatol Venereol 2011; 25: 27-32.
66. Jarratt M, Breneman D, Gottlieb AB, et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: 367-373.
67. Jarratt M, Davis JG, Giltner MP, Jones ML, Peets EA,. Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%: correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Adv Ther 1991; 8: 103-111.
68. Feldman SR, Ravis SM, Fleischer ABJ, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001; 5: 386-389. (Pubitemid 34041754)
69. Duweb GA, Abuzariba O, Rahim M, et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000; 20: 65-68. (Pubitemid 32289621)
70. Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107-113.
71. Andreassi L, Giannetti A, Milani M,. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003; 148: 134-138. (Pubitemid 36114874)
72. Pacifico A, Daidone R, Peris K,. A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 153-157. (Pubitemid 43740514)
73. Griffiths CE, Tranfaglia MG, Kang S,. Prolonged occlusion in the treatment of psoriasis: a clinical and immunohistologic study. J Am Acad Dermatol 1995; 32: 618-622.
74. Fiskerstrand EJ VG,. Weekly treatment of psoriasis vulgaris with corticosteroids and a hydrocolloid dressing is superior to the steroid alone or to UVB. J Dermatol Treat 1992; 3: 53-55.
75. David M, Lowe NJ,. Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989; 21: 511-514. (Pubitemid 19221194)
76. Volden G, Kragballe K, Van De Kerkhof PC, et al. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatol Treat 2001; 12: 141-144. (Pubitemid 33116875)
77. Galbiati G, Bonfacini V, Candiani F,. Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris. J Int Med Res 1983; 11: 31-33. (Pubitemid 13178072)
78. Faber W.R, Van Joost Th, De Hoop D, et al. Effectiveness and usability of short-time treatment of psoriasis vulgaris with two different corticosteroids under occlusion with a hydrocolloid dressing (Contreet(R)). J Eur Acad Dermatol Venereol 1995; 5: 2.
79. Dezfoulian B, De La Brassinne M, Rosillon D,. A new generation of hydrocolloid dressings in combination with topical corticosteroids in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1997; 9: 50-53. (Pubitemid 27362374)
80. The Actiderm Multi-Center Study Group. A trial of the Actiderm dermatological patch and topical corticosteroids in the treatment of psoriasis vulgaris. Cutis. 1990; 46: 84-88.
81. Van de Kerkhof PC, Chang A, van der Walle HB, et al. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Acta Derm Venereol 1994; 74: 143-146. (Pubitemid 24102479)
82. Schmidt H, Hjorth N, Salde L,. A double-blind trial of budesonide ointment and betamethasone-17-valerate ointment in psoriasis. J Int Med Res 1981; 9: 236-238. (Pubitemid 11104721)
83. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: 269-274.
84. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39: 447-450. (Pubitemid 28417383)
85. Devaux S, Castela E, Archier A, et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 52-60.
86. Mason AR, Mason J, Cork M, et al., Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; 1: CD005028.
87. Poulin Y, Papp K, Bissonnette R, et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85: 43-50.